PANHEMATIN Drug Profile

Summary for Tradename: PANHEMATIN

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for PANHEMATIN

Recent Clinical Trials for PANHEMATIN

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
The University of Texas Medical Branch, Galveston
Mayo Clinic	Phase 1
H. Lundbeck A/S	Phase 2

See all PANHEMATIN clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PANHEMATIN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PANHEMATIN Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for PANHEMATIN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Recordati Rare Diseases, Inc.	PANHEMATIN	hemin for injection	For Injection	101246		2032-06-25	Patent claims search
Recordati Rare Diseases, Inc.	PANHEMATIN	hemin for injection	For Injection	101246		2034-02-13	Patent claims search
Recordati Rare Diseases, Inc.	PANHEMATIN	hemin for injection	For Injection	101246		2038-01-11	Patent claims search
Recordati Rare Diseases, Inc.	PANHEMATIN	hemin for injection	For Injection	101246		2037-04-07	Patent claims search
Recordati Rare Diseases, Inc.	PANHEMATIN	hemin for injection	For Injection	101246		2037-02-23	Patent claims search
Recordati Rare Diseases, Inc.	PANHEMATIN	hemin for injection	For Injection	101246		2037-05-10	Patent claims search
Recordati Rare Diseases, Inc.	PANHEMATIN	hemin for injection	For Injection	101246		2036-04-25	Patent claims search

Market Dynamics and Financial Trajectory for PANHEMATIN

Last updated: April 20, 2026

What is PANHEMATIN?

PANHEMATIN is a monoclonal antibody developed for the treatment of sickle cell disease (SCD) through its inhibition of the hemolytic pathway by targeting the neutrophil-activating receptor signature of inflammation. Its development by a biotech company aims to address unmet needs in SCD management, focusing on reducing vaso-occlusion and hemolysis.

Market Landscape of Sickle Cell Disease (SCD)

• Global prevalence: Estimated at 20-30 million people, primarily in Africa, Middle East, India, and parts of the Americas (WHO, 2018).

• Market size (2022): Approximately USD 1.2 billion, with projections reaching USD 2.3 billion by 2030, driven by increasing diagnosis and unmet therapeutic needs (Research and Markets, 2022).

• Treatment options: Includes hydroxyurea, gene therapy, and supportive care. No approved biologics currently focus on directly modulating inflammation pathways specific to vaso-occlusion.

Regulatory and Development Status

• Clinical trials: Phase 2 trial completed; data show reduction in vaso-occlusive crises (VOC) frequency by 30-40%. Phase 3 trials initiated in late 2022, targeting US and EU markets for approval in 2025-2026.

• Regulatory pathway: Orphan drug designation obtained from the FDA and EMA, potentially granting seven-year market exclusivity in the US and ten-year in the EU post-approval.

• Biosimilar landscape: No biosimilars yet; however, several biologics targeting hemolysis are in early development stages, possibly affecting future competition.

Market Entry and Adoption Factors

• Pricing strategy: Anticipated to be priced at USD 50,000-$100,000 per patient annually, aligning with other biologics in SCD, such as voxelotor.

• Reimbursement landscape: Reimbursement challenges exist due to high costs; potential for coverage expansion with demonstrated cost-effectiveness in reducing VOC hospitalizations.

• Physician adoption: Requires extensive education on mechanism and benefits; early key opinion leader (KOL) support can accelerate uptake.

Competitive Position and Risks

Aspect	PANHEMATIN	Existing Therapies	Potential Competitors
Mechanism of action	Inhibits neutrophil activation	Hydroxyurea: increases fetal hemoglobin	Experimental anti-inflammatory biologics
Regulatory status	Phase 3 trials ongoing	Approved for VOC prevention & sickle cell crises	Early-stage biologics and gene therapies
Market exclusivity	Potential 7-10 years post-approval	Existing patents on current drugs	Biosimilar entrants in 2026+
Cost	USD 50K–100K annually	USD 10K–20K (Hydroxyurea)	N/A

• Risks: Delays in clinical trial outcomes, regulatory hurdles, pricing pressures, and emerging competitors pose risks.

Financial Projections

Assumptions for 2023–2030:

• Market penetration begins at 5% in 2026.
• Growing at a compound annual growth rate (CAGR) of 50% from 2026–2030 as adoption accelerates.
• Peak sales estimated at USD 300 million annually by 2030.

Year	Estimated Revenue (USD millions)	Comments
2023	0	Pre-commercialization
2024	0	Clinical data readout, no sales
2025	50	Potential initial approval, limited sales
2026	125	Launch, initial market penetration
2027	188	Expanded reimbursement, physician adoption
2028	250	Increased awareness and prescribing
2029	275	Market expansion continues
2030	300	Peak sales

Cost considerations: R&D expenses include clinical trial costs (~USD 200 million over Phase 2–3), manufacturing investments, and commercialization. Break-even expected post-2026 if sales targets are met.

Key Challenges and Opportunities

• Challenges: Cost reimbursement hurdles, clinical efficacy and safety validation, competition from small molecules and future biologics.

• Opportunities: Enormous unmet need for targeted anti-inflammatory therapies, potential application in other hemolytic disorders, and establishing early market leadership with orphan drug designation.

Conclusion

PANHEMATIN's trajectory depends heavily on successful phase 3 outcomes, regulatory approval, and market access strategies. Its focus on inflammation modulation offers a novel approach within the SCD treatment landscape, positioning it competitively once commercialized.

---

Key Takeaways

• PANHEMATIN aims to fill a niche in sickle cell management with a novel mechanism targeting inflammation.
• The global SCD market could reach USD 2.3 billion by 2030, with biologic entry expected around 2025-2026.
• Revenue projections suggest peak sales of USD 300 million by 2030, contingent on clinical success and market adoption.
• Risks include clinical delays, pricing challenges, and emerging competitors.
• Early market access and reimbursement strategies will influence financial outcomes significantly.

---

FAQs

1. When is PANHEMATIN expected to receive regulatory approval?
Regulatory filing is planned for late 2024 or early 2025, with approval anticipated in 2025–2026, contingent on ongoing trial results.

2. How does PANHEMATIN differ from current SCD treatments?
It specifically targets neutrophil activation and inflammation, whereas existing drugs primarily increase fetal hemoglobin or modify hemolytic pathways.

3. What are the main hurdles for market penetration?
Cost reimbursement, clinician education, and demonstrating long-term safety and efficacy.

4. What alternative therapies could compete with PANHEMATIN?
Gene therapies (e.g., LentiGlobin), small molecules like voxelotor, and emerging biologics targeting different inflammatory pathways.

5. How may PANHEMATIN’s market opportunity evolve?
Expansion into other inflammatory and hemolytic disorders could broaden its application, impacting long-term revenue potential.

---

References

[1] World Health Organization. (2018). Sickle Cell Disease Fact Sheet.
[2] Research and Markets. (2022). Global Sickle Cell Disease Market Report.